Analysis of >7700 Indian patients in ICOM-D cohort reveals:
- near complete overlap (98%) between NAFLD and MASLD
- comparable disease severity and non-invasive test performance in NAFLD and MASLD
https://t.co/5tum9ugjCW
@ajay_duseja@HepatologyPGI@JHepatology@RoyAHep
🔸Acute esophageal necrosis (AEN), an uncommon condition may sometimes manifest as hematemesis🩸
🔸It can occur in the setting of acute alcohol intoxication and may occasionally obscure an underlying life-threatening condition.
🌟We got 2 recently reported cases 🌟
🔥 Case 1: AEN secondary to alcohol intoxication and diabetic keto-acidosis
https://t.co/L4JEdV1SeF
🔥 Case 2: AEN concealing an underlying esophageal adenocarcinoma
https://t.co/68sThyhpBC
🔥Duodenal TB is a rare form of gastrointestinal TB (1-6%)🔥
👉🏼Gastric outlet obstruction is an uncommon presentation
👉🏼Timely diagnosis and early initiation of ATT may obviate the need for more invasive endoscopic or surgical interventions
👉🏼We report a case of young female presented with GOO and later diagnosed with duodenal TB
https://t.co/DWQ7M4Tafp
Outstanding (open access) review on metabolic, cardiovascular, and renal benefits of glucagon-like receptor agonists and next-generation incretin-based medications.
https://t.co/Yxzns6x5Oa
🔑Nutrition is so important in Liver disease.
🔥Hot off the press
✅ACLF-Intensive Nutrition improves survival & frailty
✅MELD & AARC ⬇️
⬇️ Hospitalization rates
👇👇👇Clinical Gastroenterology & Hepatology
doi: 10.1016/j.cgh.2024.09.021.
CPLD-2024
19th-20th October, Chandigarh
We are all set to welcome the Hepatology community of the country to Chandigarh for 24th - PGI-AIIMS- SGPGI - Current Perspectives in Liver Disease
A not to be missed Academic Bonanza in Liver Disease
https://t.co/HxSiwrR4Ow
Pilot double-blind RCT on Dapagliflozin in recurrent ascites
-Significantly better ascites control and natriuresis with Dapa
-No diff in CTP, MELD or survival between Dapa and placebo
-Increased AKI and infections with Dapa
@HepatologyPGI#GITwitter
https://t.co/ArjLtZZRmD
🔸Out in print : Measures to classify SLD 🇮🇳 cohort
🔸Revisiting ANI to identify Met-ALD
🔸📈 40% ever 🍷consumers
🔸ANI 👍 at xtremes but underperforms in grey zones
🔸GGT ❎
🔸Similar MRPDFFs
@doc_arka@AnandVKulkarni2@ajay_duseja@DrLoomba@LiverFellow https://t.co/3y73PSMem1
🔸Its🔑 to identify ACLF early
🔸We ❓ what transitions AD ➡️ ACLF
🔸Simple indicators: 3cohorts
➡️Failing Liver
➡️Portal Hypertension Severity
➡️Systemic Inflammation
Works in ALD ➕ MASLD cohorts
👁️ AD ➡️ACLF
@nipun29j @AmCollegeGastro@DrArunKValsan https://t.co/YpchhaHNbO
Original Article: Central obesity is an independent determinant of advanced fibrosis in lean patients with non-alcoholic fatty liver disease (NAFLD)
By Arka De et al
https://t.co/Gx1PoSEfFL
#LiverTwitter#GITwitter#Obesity
Tuberculosis masquerading as a pancreatic cyst in a patient with cirrhosis and significant weight loss
https://t.co/KbJntpXV6K
@HepatologyPGI#GItwitter#livertwitter